BriaCell Therapeutics Corp. (BCTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $4.22, BCTX has negative trailing earnings (P/E not meaningful) and an ROE of -147.92%. Market capitalisation stands at $37M.
Balance sheet quality for BCTX: current ratio of 5.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $4.22 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 1.25 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -147.92% |
| Return on Invested Capital | -136.31% |
| Return on Assets | -113.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.07 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics Corp. | $37M | 1.25 | -147.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX
Explore sector: Healthcare · Biotechnology
More sections of BCTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks